Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
• Dapagliflozin – a sodium-glucose co-transporter 2 inhibitor working independently of insulin. • Long term diabetes-related complications are estimated by a Cardiff simulation model. • Data from a 52-week trial comparing dapagliflozin and SU in combination with metformin is used. • Metformin+dapagl...
Ausführliche Beschreibung
Bibliographische Detailangaben
Veröffentlicht in: | A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients. - 2016. - Amsterdam [u.a.]
|
1. Verfasser: |
Sabale, Ugne
(VerfasserIn) |
Weitere Verfasser: |
Ekman, Mattias
(BerichterstatterIn),
Granström, Ola
(BerichterstatterIn),
Bergenheim, Klas
(BerichterstatterIn),
McEwan, Phil
(BerichterstatterIn) |
Format: | Online-Aufsatz
|
Sprache: | English |
Veröffentlicht: |
2015
|
Zugriff auf das übergeordnete Werk: | A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
|
Schlagworte: | Economic modeling
Dapagliflozin
Sulfonylurea
Type 2 diabetes mellitus
Cost-effectiveness |
Umfang: | 9 |